Dövizler / LXRX
LXRX: Lexicon Pharmaceuticals Inc
1.10
USD
0.05
(4.35%)
LXRX fiyatı bugün -4.35% değişti. Gün boyunca enstrüman, Düşük fiyatı olarak 1.09 ve Yüksek fiyatı olarak 1.15 aralığında işlem gördü.
Lexicon Pharmaceuticals Inc hareketlerini izleyin. Gerçek zamanlı fiyatlar, piyasa değişikliklerine hızlı bir şekilde tepki vermenize yardımcı olacaktır. Farklı zaman dilimleri arasında geçiş yaparak döviz kurunun trendlerini ve hareketlerini dakika, saat, gün, hafta ve ay bazında takip edebilirsiniz. Piyasa değişikliklerini tahmin etmek ve bilinçli alım-satım kararları vermek için bu bilgileri kullanın.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
LXRX haberleri
- Lexicon Pharmaceuticals’ Strategic Retrenchment Will Take Years To Show Results (LXRX)
- Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know
- Jefferies raises Lexicon Pharmaceuticals stock price target to $0.85
- Lexicon Q2 2025 slides: Strategic pivot yields profit as pipeline advances
- Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates
- Lexicon earnings beat by $0.10, revenue topped estimates
- Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates
- Lexicon Pharmaceuticals regains Nasdaq compliance
- Lexicon Pharmaceuticals regains Nasdaq compliance for minimum bid price
- Lexicon Q1 2025 slides: EPS beat, revenue miss, strategic partnerships advance
- H.C. Wainwright reiterates buy rating on Lexicon Pharmaceuticals stock
- Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
- Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple
- Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple
- Lexicon Pharmaceuticals surges 67% following InvestingPro’s Fair Value signal
- Lexicon Pharmaceuticals at Jefferies Conference: Strategic Partnerships and Pipeline Progress
- Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
- Lexicon at H.C. Wainwright Conference: Strategic Pipeline Developments
- SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology
- Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price
- Top 2 Health Care Stocks That May Crash This Month - Lexicon Pharmaceuticals (NASDAQ:LXRX), Amarin Corp (NASDAQ:AMRN)
- US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst - Babcock & Wilcox (NYSE:BW), AAR (NYSE:AIR)
- Lexicon's Drug Discovery Engine Validated By Novo's Obesity Drug Deal
- Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected - Lexicon Pharmaceuticals (NASDAQ:LXRX), DBV Technologies (NASDAQ:DBVT)
Günlük aralık
1.09
1.15
Yıllık aralık
0.28
2.18
- Önceki kapanış
- 1.15
- Açılış
- 1.13
- Satış
- 1.10
- Alış
- 1.40
- Düşük
- 1.09
- Yüksek
- 1.15
- Hacim
- 1.227 K
- Günlük değişim
- -4.35%
- Aylık değişim
- 2.80%
- 6 aylık değişim
- 197.30%
- Yıllık değişim
- -36.42%
31 Ağustos, Pazar